摘要
目的探讨血清中细胞间粘附分子-1(Intercellular adhesion molecule-1,ICAM-1)的水平与2型糖尿病肾病(Diabetic nephropathy,DN)病变程度的关系。方法选择2017年4月~2019年1月在我院住院2型糖尿病及健康体检者共265例分为五组[对照组、非DN组、早期DN组、临床期DN组(肾功能正常)、临床期DN组(肾功能异常)],观察各组ICAM-1与UAER的关系。结果1.DN各组ICAM-1明显增高,且随着DN病情的加重,ICAM-1水平逐渐升高(对照组:48.00±13.10 ng/mL;非DN组:203.02±30.55 ng/mL;早期DN组:400.32±55.78 ng/mL;临床期DN组(肾功能正常):601.12±51.81 ng/mL;临床期DN组(肾功能异常):863.71±36.44 ng/mL)。2.DN各组UAER均与ICAM-1呈正相关(早期DN组:UAER与ICAM-1的相关系数r=0.789,临床期DN组(肾功能正常):UAER与ICAM-1的相关系数r=0.719,临床期DN组(肾功能异常):UAER与ICAM-1的相关系数r=0.510)。结论ICAM-1与DN病变程度相关,可作为反映DN病情严重程度的参考指标,也可作为DN早期筛查的参考指标。
Objective To investigate the relationship between the level of intercellular adhesion molecule-1(ICAM-1)in serum and the degree of lesions of type 2 diabetic nephropathy(DN).Methods A total of 265 hospitalized patients with type 2 diabetes and healthy subjects in our hospital from April 2017 to January 2019 were selected and divided into five groups[control group,non-DN group,early DN group,clinical stage DN group(normal renal function),clinical stage DN group(abnormal renal function)].The relationship between ICAM-1 and UAER in each group was observed.Results 1.ICAM-1 was increased significantly in each group of DN,and the level of ICAM-1 was gradually increased with the worsening of DN disease(control group:48.00±13.10 ng/mL;non-DN group:203.02±30.55 ng/mL;early DN group:400.32±55.78 ng/mL;clinical stage DN group(normal renal function):601.12±51.81 ng/mL;clinical stage DN group(renal dysfunction):863.71±36.44 ng/mL).2.The UAER of each group of DN was positively correlated with ICAM-1(early DN group:the correlation coefficient of UAER and ICAM-1 was r=0.789;clinical stage DN group(normal renal function):correlation coefficient between UAER and ICAM-1 was r=0.719;clinical stage DN group(renal dysfunction):the correlation coefficient between UAER and ICAM-1 was r=0.510).Conclusion ICAM-1 is related to the degree of DN lesions,and can be used as a reference index to reflect the severity of DN disease.It can also be used as a reference index for early screening of DN.
作者
朱虹
刘铁奇
ZHU Hong;LIU Tieqi(Department of Endocrinology,the Second Hospital of Chaoyang in Liaoning Province,Chaoyang122000,China;Department of Neurosurgery,the Second Hospital of Chaoyang in Liaoning Province,Chaoyang122000,China)
出处
《中国现代医生》
2020年第12期22-25,29,共5页
China Modern Doctor